Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia
Open Access
- 11 September 2019
- journal article
- review article
- Published by Springer Science and Business Media LLC in Biomarker Research
- Vol. 7 (1), 1-6
- https://doi.org/10.1186/s40364-019-0170-2
Abstract
FMS-like tyrosine kinase 3- internal tandem duplication (FLT3-ITD) remains as one of the most frequently mutated genes in acute myeloid leukemia (AML), especially in those with normal cytogenetics. The FLT3-ITD and FLT3-TKD (tyrosine kinase domain) mutations are biomarkers for high risk AML and are associated with drug resistance and high risk of relapse. Multiple FLT3 inhibitors are in clinical development, including lestaurtinib, tandutinib, quizartinib, midostaurin, gilteritinib, and crenolanib. Midostaurin and gilteritinib have been approved by FDA for Flt3 mutated AML. Gilteritinib (ASP2215, Xospata) is a small molecule dual inhibitor of FLT3/AXL. The ADMIRAL study showed that longer overall survival and higher response rate are associated with gilteritinib in comparison with salvage chemotherapy for relapse /refractory (R/R) AML. These data from the ADMIRAL study may lead to the therapy paradigm shift and establish gilteritinib as the new standard therapy for R/R FLT3-mutated AML. Currently, multiple clinical trials are ongoing to evaluate the combination of gilteritinib with other agents and regimens. This study summarized clinical trials of gilteritinib for AML.Keywords
This publication has 60 references indexed in Scilit:
- How I treat the older patient with acute myeloid leukemiaBlood, 2015
- Deletion and deletion/insertion mutations in the juxtamembrane domain of the FLT3 gene in adult acute myeloid leukemiaLeukemia Research Reports, 2014
- Crenolanib is active against models of drug-resistant FLT3-ITD−positive acute myeloid leukemiaBlood, 2013
- Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid LeukemiaNew England Journal of Medicine, 2012
- Clinical Effect of Point Mutations in Myelodysplastic SyndromesNew England Journal of Medicine, 2011
- How I treat acute myeloid leukemiaBlood, 2010
- Genomic, immunophenotypic, and NPM1/FLT3 mutational studies on 17 patients with normal karyotype acute myeloid leukemia (AML) followed by aberrant karyotype AML at relapseCancer Genetics and Cytogenetics, 2010
- The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicinCell Cycle, 2009
- Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemiaBlood, 2004
- SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivoBlood, 2003